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Background: The recent discovery of a new myokine (irisin) potentially involved in health-related training effects
has gained great attention, but evidence for a training-induced increase in irisin remains preliminary. Therefore,
the present study aimed to determine whether irisin concentration is increased after regular exercise training
in humans.
Methods: In a randomized controlled design, two guideline conforming training interventions were studied.
Inclusion criteria were age 30 to 60 years, <1 hour/week regular activity, non-smoker, and absence of major
diseases. 102 participants could be included in the analysis. Subjects in the training groups exercised 3 times per
week for 26 weeks. The minimum compliance was defined at 70%. Aerobic endurance training (AET) consisted of
45 minutes of walking/running at 60% heart rate reserve. Strength endurance training (SET) consisted of 8 machine-
based exercises (2 sets of 15 repetitions with 100% of the 20 repetition maximum). Serum irisin concentrations in
frozen serum samples were determined in a single blinded measurement immediately after the end of the training
study. Physical performance provided positive control for the overall efficacy of training. Differences between
groups were tested for significance using analysis of variance. For post hoc comparisons with the control group,
Dunnett’s test was used.
Results: Maximum performance increased significantly in the training groups compared with controls
(controls: ±0.0 ± 0.7 km/h; AET: 1.1 ± 0.6 km/h, P < 0.01; SET: +0.5 ± 0.7 km/h, P = 0.01). Changes in irisin did not
differ between groups (controls: 101 ± 81 ng/ml; AET: 44 ± 93 ng/ml; SET: 60 ± 92 ng/ml; in both cases: P = 0.99
(one-tailed testing), 1−β error probability = 0.7). The general upward trend was mainly accounted for by a negative
association of irisin concentration with the storage duration of frozen serum samples (P < 0.01, β = −0.33). After
arithmetically eliminating this confounder, the differences between groups remained non-significant.
Conclusions: A training-induced increase in circulating irisin could not be confirmed, calling into question its
proposed involvement in health-related training effects. Because frozen samples are prone to irisin degradation
over time, positive results from uncontrolled trials might exclusively reflect the longer storage of samples from
initial tests.
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Although the existence of health-promoting effects of
regular physical exercise is beyond doubt, our knowledge
about the underlying molecular, cellular, and systemic
mechanisms involved in such effects is still fragmentary.
In 2012 a new muscle-derived messenger substance
(myokine) was described. This newly identified myokine
was named ‘irisin’ after the Greek messenger goddess Iris
[1], and presumably is an important link within the
causal chains leading from physical activity to better
health [1]. This finding has received great attention, and
resulted in a wealth of comments and secondary publi-
cations [2-8]. In their original work, Boström et al. [1]
unfolded an impressive line of evidence for the health-
related benefits of irisin, starting with the observation of
improved health and longevity in transgenic mice with
mild overexpression of peroxisome proliferator-activated
receptor gamma coactivator-1α (PGC-1α) in muscle,
which is a model for the well-known induction of PGC-1α
by physical exercise. The ensuing experiments led to the
characterization of a membrane protein (FNDC5) that is
expressed under control of PGC-1α in skeletal muscle.
The extracellular part of FNDC5, cleaved and secreted
into the extracellular space, causes similar systemic effects
to those seen in the mouse model, namely, increased en-
ergy expenditure and weight loss, and improved glucose
homeostasis.Figure 1 Trial design. CON, control group; AET: aerobic endurance traininThe initial results [1] were derived mainly from experi-
ments using transgenic animals and cultured cells. Their
external validity was substantiated in wild-type mice and
humans by a significant, training-induced increase in
FNDC5 expression in skeletal muscle and by an increase
in the serum concentration of irisin. In humans, a two-
fold increase in circulating irisin after a training period
of 10 weeks was reported; however, given the low subject
number (n = 8) and lack of a control group, this result
has only a preliminary character. In the meantime, two
studies were unable to reproduce a substantial, training-
induced increase in FNDC5 expression [9] or circulating
irisin [10]. However, randomized controlled trials (RCTs)
are still lacking. Therefore, we determined the concen-
tration of irisin in the serum of 102 subjects from a pro-
spective RCT of training. In addition, we assessed the
proposed influencing factors of baseline irisin concentra-
tion and the respective training-induced changes.
Methods
General design
The study was a prospective RCT of training with an
intervention period of 6 months. Two guideline-compliant
preventive training programs (aerobic endurance training
(AET) [11,12] and strength endurance training (SET)
[12,13]) were studied in parallel groups (Figure 1). All tests
were conducted at Saarland University.g; SET: strength endurance training.
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The present investigation was carried out in accordance
with the declaration of Helsinki and approved by the
local ethics committee (Ärztekammer des Saarlandes, ID
148/10). All participants provided written informed con-
sent prior to participation.
Subjects
Subjects were selected to represent typical healthy par-
ticipants in preventive training. Inclusion criteria were:
age 30 to 60 years, untrained status (<1 hour/week regu-
lar activity for at least 1 year), non-smoker, body mass
index <30 kg/m2, no major diseases or disorders that
would interfere with the intended training or require
regular medication (including fasting blood glucose con-
centration <6.1 mmol/l, resting blood pressure <160/100
mmHg, presence of iron deficiency/anemia). Subjects
were recruited by advertisements in local media and at
informative events. Randomization was performed as
simple random allocation; each subject identifier was
forwarded to a person who had no further relationship
to the conduct of the study, and who performed the
randomization blindly using a computer list.
Serum collection and handling
Testing sessions were scheduled before the training
period and at 2 to 7 days after the final training bout.
Subjects were instructed to abstain from physical exer-
cise between the final training bout and the final test.
Participants reported to the laboratory between 08.00
and 10.00 hours after an overnight fast; the time of day
was held constant for every subject (± 30 minutes). Ve-
nous blood samples were taken from the antecubital
vein after a supine resting period of at least 10 minutes.
Blood samples were centrifuged immediately after col-
lection, and serum aliquots were stored frozen at −20°C
until analysis. Glucose, insulin, and cholesterol were ana-
lyzed by routine techniques (UniCell DxC 600 Synchron;
Beckmann Coulter GmbH, Krefeld, Germany).
Determination of circulating irisin
A commercial ELISA kit [10] (Phoenix Pharmaceuticals,
Burlingame, CA, USA) was used to determine the serum
concentration of irisin, which was measured by a Sunrise
microplate reader (Tecan, Männedorf, Switzerland). The
lot-specific protocol supplied by the manufacturer was
fully respected. With each 96-well plate, a standard solu-
tion with an irisin concentration of 41.0 ng/ml (supplied
by hoenix Pharmaceuticals) was measured. The 10 mea-
surements gave a value ± standard deviation (SD) of
41.3 ± 1.8 ng/ml. To minimize differences in the handling
of the individual wells of the immunoplates used for this
assays, a semi-automatic 96-channel pipettor (Selma,
CyBio AG, Jena, Germany) was used. All measurementswere performed within one experiment immediately after
completion of the training study, and samples were pre-
pared in triplicate. Sample values were determined by
extrapolation to a standard curve (determined for each
measurement) using the curve-fitting procedure in Matlab
(MathWorks, Ismaning, Germany). All samples were
coded to ensure blinding of the test operator.
Anthropometry
Height and weight were measured for all participants
while they were wearing light sports clothes without
shoes. Body mass index (BMI) was calculated as weight
(kg) divided by height squared (m2). Body fat percent-
age was determined with a Harpenden skinfold caliper
(Wilken, Berlin, Germany) using the 10-point method
[14]. Waist circumference was measured halfway bet-
ween the lower rib and the iliac crest in a horizontal
plane. Hip circumference was measured as the widest
horizontal circumference over the buttocks.
Exercise testing
Exhaustive exercise tests were carried out on a motor-
driven treadmill (Woodway ELG 70, Woodway GmbH,
Germany) using a combined step-wise and ramp-wise
protocol as previously published [15,16]. In brief, an
initial step-wise phase (step duration: 3 minutes, step in-
crement: 1 km/h), intended for the determination of
submaximal heart rate curves, was followed by a ramp-
shaped phase (ramp increment: 0.8 km/h/min) to allow
for the valid determination of maximum physical capa-
city. Initial velocity was chosen as between 3 and 7 km/h,
according to subject characteristics (gender, age, BMI).
The individual protocol from the initial test (initial vel-
ocity and number of steps) was held constant for the final
test. Treadmill incline was 0.5 degrees. Maximum heart
rate (≥200 minus age (years)) and blood lactate concentra-
tion (≥8 mmol/l) were used as indicators of exhaustion,
and maximum physical performance was analyzed only in
subjects who fulfilled these criteria in both exercise tests.
Capillary blood samples for the determination of blood
lactate concentrations were taken from the hyperemized
left earlobe at rest and 2 minutes after cessation of exer-
cise. Samples were immediately hemolyzed, and analysis
was carried out using an enzymatic amperometric system
(Super GL, Greiner, Flacht, Germany). The test operators
were blinded to subject allocation.
Interventions
Subjects in the training groups exercised 3 times/week for
26 weeks. The minimum compliance to allow inclusion in
the final analyses was defined at 70% (55 training sessions).
Aerobic endurance training (AET) consisted of 45
minutes of walking/running at 60% heart rate reserve.
Heart rate monitors with integrated memory function
Figure 2 Association between sample storage duration and
serum irisin concentration. Data points represent baseline values
of all groups and final tests of control subjects.
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ipant’s personal heart rate prescription (± 5 beats/min)
were provided to the participants for control and docu-
mentation of training. Participants were required to attend
at least one supervised training session per week. At this
occasion training and heart rate logs were inspected.
Strength endurance training (SET) consisted of eight
machine-based exercises (back extension and crunch;
Dr Wolff, Arnsberg, Germany), pulldown, seated row,
seated leg curl, seated leg extension, seated chest
press, and lying leg press (gym80 International,
Gelsenkirchen, Germany). Two sets of 15 repetitions
with 100% of the 20 repetition maximum were per-
formed for each exercise. For SET, all training sessions
were performed under the supervision of study staff.
Participants in the control group were advised not to
change their previous sedentary lifestyle. Regular phone
contact ensured compliance.
Statistical analysis
Distributions of categorical variables were tested by the
Kruskal-Wallis test. For continuous variables, normal
distribution was checked by the Shapiro-Wilk test. If ap-
propriate, variables were log-transformed for statistical
testing. Differences between groups were tested for sig-
nificance using analysis of variance (ANOVA). For post
hoc comparisons with the control group Dunnett’s test
was used (one-tailed, in accordance with the study
hypothesis). Multiple regression analysis was used to
analyze influencing factors on baseline irisin levels and
training-induced changes, respectively. The two training
groups (AET and SET) were pooled for regression ana-
lysis of training-induced changes. Effects coding was
used for nominal parameters.
We found an unexpected effect of sample storage
duration on irisin concentration, therefore arithmetical
correction for this confounding factor was performed.
For this additional calculation, baseline values from all
groups were pooled with the final tests of control sub-
jects in order to obtain data points with a wide range of
storage periods (range 17 to 782 days). Irisin concentra-
tions were plotted against the storage period, and linear
regression was performed (Figure 2). Correction of irisin
concentrations was based on the slope of the regression
line (0.184 ng/ml/day).
The significance level for the α-error was set at P < 0.05.
Data are presented as means ± SD if not otherwise in-
dicated. The Statistica 7 software package (StatSoft,
Hamburg, Germany) was used for data analysis.
Results
Baseline subject characteristics
Baseline subject characteristics are summarized in Table 1.
There were no significant differences between groups.Physical performance
In total, 95 subjects fulfilled the exhaustion criteria in
both exercise tests (Con 36; AET 21; SET 38) and were
included in the analysis of maximum performance. Maxi-
mum performance in the treadmill test increased signifi-
cantly in the AET and SET groups compared with the
control group (Figure 3A).
Courses of submaximal exercise heart rate during
the step-wise phase of the exercise tests are depicted
in Figure 3B. The clear downward shift in AET was
substantiated by the significant group × test × step
interaction (P = 0.039).Baseline irisin concentration
Mean baseline irisin concentration was 194 ± 62 ng/ml.
There were no significant differences between groups
(Table 1). Based on a panel of previously described pre-
dictors [9,10,17,18] only age (P = 0.029, β = −0.20) and
total cholesterol (P = 0.015, β = 0.20) showed a signifi-
cant, independent influence on circulating irisin levels.
Other, but non-significant, predictors in the model
were sex (P = 0.089, β = 0.23), BMI (P = 0.362, β = 0.13),
percentage body fat: (P = 0.119, β = −0.22), maximum
physical performance (P = 0.474, β = −0.08), and in-
sulin level (P = 0.068, β = 0.17). However, the stron-
gest predictor was the duration of the storage period
of frozen serum samples (P < 0.001; β = −0.33). When
irisin concentrations were corrected for storage du-
ration using the slope of the regression line (0.184
ng/ml/day) the following values were obtained: overall
mean: 307 ± 63; control 302 ± 77; AET 311 ± 56; SET
311 ± 51 ng ±ml (no significant differences between
groups).
Table 1 Baseline subject characteristics
Characteristic* Control (n = 39) AET (n = 23) SET (n = 40) P
Participants (female/male), n 39 (26/13) 23 (15/8) 40 (23/17) 0.675
Age, years 50 ± 7 49 ± 7 48 ± 7 0.370
BMI, kg/m2 24.5 ± 3.1 23.5 ± 3.5 24.9 ± 3.4 0.253
Body fat, % 24 ± 5 23 ± 4 23 ± 5 0.652
Vmax,, km/h 10.0 ± 1.5 10.3 ± 1.7 10.0 ± 1.4 0.921
Irisin,, ng/ml 188 ± 75 201 ± 52 196 ± 51 0.713
Insulin, mU/l2 4.8 ± 2.1 4.4 ± 2.3 5.2 ± 2.8 0.513
Cholesterol, mg/dl2 211 ± 38 221 ± 40 206 ± 43 0.375
AET, aerobic endurance training; BMI, body mass index; SET, strength endurance training; Vmax, maximum performance in the exercise test.
1Values are mean ± SD unless otherwise stated.
2SI conversion factors: to convert insulin to pmol/l, multiply values by 6.945; to convert cholesterol to mmol/L, multiply values by 0.0259.
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Changes in raw values of circulating irisin are displayed
in Figure 4. There were no significant differences be-
tween groups. (P = 0.99 in both cases; 1−β error prob-
ability = 0.7). The general upward trend in all groups
was mainly accounted for by the longer storage of sam-
ples from initial tests. Figure 4 displays the changes after
arithmetically correcting for this confounder (P = 0.99 in
both cases, 1−β = 0.7).
No relation between changes in circulating irisin in
the training groups and age, gender, BMI, or baseline
irisin concentration was found by multiple regression
analysis (age: P = 0.911, β = −0.01; gender: P = 0.997,
β < 0,01; BMI: P = 0.353, β = 0.14, baseline irisin: P = 0.158,
β = −0.18). However, from the individual assessment of
outliers (below or above the mean ± 2 standard deviations)
it is noteworthy that six of the eight low respondersFigure 3 Changes in physical performance over the intervention peri
indicate differences from control group (post hoc Scheffé test). (B) Courses
(a-c) on x-axes indicate the final three steps preceding the transgression to
interaction: P = 0.039.were male, whereas eight of the ten high responders
were female.
Discussion
Irisin has been described as a new muscle-derived mes-
senger substance (myokine), which may be involved in
the mediation of systemic, health-related benefits from
regular physical exercise. Although the original paper
identifying this substance presented a stringent and con-
clusive sequence of in vitro and transgenic animal expe-
riments, the evidence for induction by exercise training
in humans remains preliminary [1]. In the present RCT,
a training-induced increase in the serum concentration
of irisin could not be shown, despite a clear increase
in physical performance, which must be considered as
a positive control for the overall efficacy of training
interventions.od. (A) Maximum running speed (mean ± standard deviation). P-values
of submaximal exercise heart rate (means ± standard error). Letters
the ramp-shaped phase of the exercise tests. Group × test × step
Figure 4 Changes in serum irisin concentration over the intervention period. (A) Raw values as measured (mean ± standard deviation).
(B) Values after correction for the influence of sample storage duration using the slope of the regression line for baseline values (0.184 ng/ml/day;
mean ± standard deviation).
Hecksteden et al. BMC Medicine 2013, 11:235 Page 6 of 8
http://www.biomedcentral.com/1741-7015/11/235In their original paper, Boström et al. [1] reported a
twofold increase in circulating irisin after 10 weeks of
endurance training in healthy, obese adult humans.
However, because of the low subject number (n = 8) and
lack of a control group, this result warrants confirma-
tion. Moreover, the statistical procedure used to test the
pre-training and post-training difference merits discus-
sion (Student’s t-test for the eight subjects after internal
normalization for pre-training values resulting in a pre-
training variance of 0). In the meantime, two further ar-
ticles have been published, which failed to substantiate a
robust, systematic training-induced increase in the ex-
pression of the irisin precursor FNDC5 [9] or in circula-
ting irisin [10]. However, interpretation was complicated
by methodological limitations in both cases.
Timmons et al. reported gene-chip data from two
training trials (6 weeks of endurance training (n = 24)
and 20 weeks of whole body strength training (n = 43),
respectively) and a cross-sectional study (young and old
groups of trained and age-matched sedentary subjects
(n = 10 per group)) [9]. A statistically significant dif-
ference in FNDC5 mRNA could only be shown between
the older endurance-trained and sedentary subjects.
Power calculations, which seem crucial in order to inter-
pret statistically insignificant results, were not provided.
The interpretation of these results is controversial,
particularly when the reported lack of association with
differences in metabolic health indicators is considered.
The authors [9] concluded that FNDC5 is not syste-
matically induced by exercise and is unlikely to play a
major role in health-related training effects. In their
reply, Boström et al. emphasized the semiquantitative
character of gene-chip analyses as a possible explanation
for the smaller effect sizes and the lack of correlation
with health indicators. However, this was only stated in
general without considering the sensitivity data provided
in the original work [9]. Boström et al. also point out
the lack of increase in the expression of PGC-1α, which
they considered a crucial positive control of trainingefficacy on the molecular level. However, although a
chronic, training-induced increase in PGC-1α is well
established on the protein level, the acute exercise-
induced increase in PGC-1α mRNA seems to be a tran-
sient phenomenon [19]. In this context, it is also surpris-
ing that two [20,21] of four [19-22] studies, referenced
to substantiate the value of PGC-1α as a positive control
for the efficacy of a prolonged training program, re-
ported on acute changes after a single bout of exercise
only. Moreover, an increase in mitochondrial enzyme ac-
tivities, undoubtedly markers of exercise-induced adap-
tation in skeletal muscle, was found in the endurance
training group by Timmons et al. [9,23], a fact that was
not considered in the reply by Boström et al.
Huh et al. [10] determined circulating irisin in serum
samples from a training study first published in 2011.
This investigation was originally designed to compare
two repeated-sprint protocols [24]. The two training
groups were apparently pooled for the retrospective ana-
lysis of circulating irisin. A significant acute increase in
circulating irisin after a bout of sprints (four or six bouts
of 80 m sprints) was found before but not after the 8
week training period. Surprisingly, the chronic training-
induced change in resting values, which is a far more
relevant marker of the proposed physiological role of iri-
sin, was not tested. Numerically, a slight decrease in iri-
sin was apparent (473.4 ± 36.4 vs. 420.3 ± 38.5 ng/ml);
however, the training protocol (four or six bouts of 80 m
sprints, 3 times/week) and the subject characteristics
(physical education students) differed widely from the
original work of Boström et al. and are not representa-
tive of preventive training.
In the present study, we could not detect any training-
induced increase in circulating irisin, despite the proven
efficacy of training interventions as documented by phy-
sical performance. Moreover, use of previously untrained
subjects and a long period of guideline-compliant exer-
cise training must be regarded as favorable for the ge-
neration of detectable training effects. Consequently, the
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work of Boström et al. [1] remain the only evidence for
an induction of circulating irisin by exercise training in
humans. Moreover, the lack of stability of irisin in frozen
serum samples, which was apparent in our data, may
lead to an erroneous increase in irisin for intra-group
comparisons, because of the shorter storage of samples
from the later tests (Figure 4). This issue is particularly
relevant because there are no details about the prepar-
ation and storage of serum samples or the delay between
completion of the training study and analysis in either
the original work by Boström et al. [1], or the publica-
tion of the training trial using human samples [25].
Predictors of circulating irisin concentration
A considerable number of anthropometric, ergometric,
and metabolic predictors of circulating irisin concen-
tration has been proposed [10,17,18,26]. Some of the
results are contradictory, most likely due to large diffe-
rences in the studied populations. In our subjects, who
were representative of healthy participants in preventive
exercise (and, thus, of the target population likely to
have possible irisin effects), only age and total choles-
terol could be identified as independent predictors of
baseline irisin concentrations, whereas measures of
adiposity, physical performance, and glucose homeosta-
sis were not.
To date, potential predictors of training-induced chan-
ges in circulating irisin have not been formally investi-
gated. However, an influence of age and adiposity has
been assumed [9] (including reply). These factors and
gender and baseline irisin concentration could not be
confirmed in our data.
Limitations
In the present study, we assessed only the concentration
of circulating irisin and the expression of FNDC5 in ske-
letal muscle has not been studied. Despite the roughly
proportional changes on the circulating protein and
mRNA levels reported by Boström et al. [1], this dif-
ference has to be considered when comparing our re-
sults with those of purely mRNA-based analyses [9].
However, only circulating irisin, but not tissue bound
FNDC5 mRNA or protein, may cause effects in remote
adipose tissue.
A time range of 2 to 7 days was allowed between the
final bout of the training exercise phase and the final test
of each subject (median: 4 days). This time lag, which
is longer than in the original study by Boström et al.
(48 hours [1]), was chosen because it is clearly longer
than the acute effect of exercise for major health-related
parameters [27,28], but still avoids de-training effects
[29-31]. Although the time course of eventual exercise-
induced changes in circulating irisin has not been studiedto date, no association between the aforementioned time
lag and training effects on circulating irisin became appa-
rent in the training groups in the present study (P = 0.656;
r = 0.06). Therefore, it is unlikely that a chronic training
effect with unusually rapid regression was missed; how-
ever, this cannot be excluded completely.
Conclusions
A general induction of irisin by regular exercise training
seems unlikely. This limits the putative role of irisin for
training-induced improvements of metabolic health. An
induction of irisin in a limited subset of people (elderly
or obese) has been reported previously [9] however, age,
sex, BMI and baseline irisin value could not be substan-
tiated as predictors in our data.
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